All data are based on the daily closing price as of February 6, 2026
l
Lunit
328130.KQ
27.42 USD
-1.20
-4.19%
Overview
Last close
27.42 usd
Market cap
800.68M usd
52 week high
58.23 usd
52 week low
23.23 usd
Target price
20.5 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
15.3273
Price/Book Value
7.1647
Enterprise Value
855.01M usd
EV/Revenue
16.3143
EV/EBITDA
-45.3273
Key financials
Revenue TTM
52.41M usd
Gross Profit TTM
52.41M usd
EBITDA TTM
-49.11M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
277.89M usd
Net debt
43.87M usd
About
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.